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CYSTICIDAL THERAPY
IMPACT ON SEIZURE CONTROL IN EPILEPSY ASSOCIATED
WITH NEUROCYSTICERCOSIS
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CARLOS ALBERTO MANTOVANI GUERREIRO, FERNANDO CENDES
ABSTRACT - Objective: To evaluate the clinical features and seizure control of epilepsy related to
neurocysticercosis. Method: 18 patients with partial epilepsy and neurocysticercosis were treated with albendazol
or praziquantel and followed from 3 months to 12 years. We analyzed results from the CSF exam, interictal
electroencephalogram (EEG), head computerized tomography and/or magnetic resonance imaging. Results: The
patients’ mean age was 36.4 years. The mean duration of epilepsy was 16 years. 83% patients had simple partial
seizures ; 17% had complex partial seizures . All patients underwent routine EEGs: 62% had abnormalities and
38% were normal. A relationship was observed between focal EEG abnormality and the location of cyst in 28%
of the patients. The CSF exams showed pleocytosis in 33% of the patients, and 28% had elevated protein levels.
Only 22% of patients had positive titer for cysticercosis in the CSF. In all patients who had somatosensory and
special sensory seizures there was a relationship between location of the cysts and seizure semiology (n=11).
After cysticidal therapy, 83% patients had a significant improvement in controlling seizures. Conclusion:  In this
group, we found a predominance of simple partial seizures and a relationship between somatosensory and special
sensory seizures and the location of the cysts. Cysticidal therapy was effective in controlling seizures in these
patients and should be considered for patients with partial seizures and semiology related to cyst location.
KEY WORDS: neurocysticercosis, albendazol, praziquantel, epilepsy, partial seizures, computerized
tomography, EEG.
Impacto do tratamento cisticida no controle das crises epilépticas relacionadas a neurocisticercose
RESUMO - Objetivo: Avaliar as características e o controle das crises em pacientes com epilepsia associada à
neurocisticercose. Método: Foram avaliados 18 pacientes tratados com albendazol ou praziquantel, com seguimento
após tratamento variando de 3 meses a 12 anos. Todos pacientes tinham LCR, EEG interictal, tomografia
computadorizada e/ou ressonância magnética de crânio. Resultados: A idade média foi de 36,4 anos. O tempo de
epilepsia foi em média 16,2 anos; 83% dos pacientes apresentavam crises parciais simples e 17%; crises parciais
complexas. O EEG foi normal em 38%. Em apenas 28% dos pacientes houve relação entre alterações focais do
EEG e a localização do cisto. Em relação ao LCR; 33% apresentavam pleiocitose, 28% hiperproteinorraquia e
apenas 22% apresentavam imunologia positiva para cisticercose . Foi observada relação entre localização do
cisto e semiologia das crises em todos os pacientes com crises de início sensitivo-motor e sensorial especial (n=
11). Após tratamento cisticida, 83% tiveram redução de pelo menos 50% das crises . Conclusão: Na epilepsia
relacionada a neurocisticercose predominam crises parciais simples e observa-se relação entre crises sensitivo-
motoras ou sensoriais especiais e localização do cisto. O tratamento cisticida deve ser considerado nos pacientes
com crises parciais com semiologia relacionada à localização do cisto.
PALAVRAS-CHAVE: neurocisticercose, albendazol, praziquantel, crises parciais, tomografia
computadorizada, EEG.
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The public health system in developing countries 1 has been unable to control
neurocysticercosis. In Brazil, the disease prevalence is between 1 to 2% 2 and its main symptoms
are: headaches, meningitis, focal neurological deficits, epileptic seizures and cognitive disorders. It is
an important cause of morbidity in young adults3- 6. Epileptic seizures are most common symptoms1,7-11.
Although most of the seizures can be controlled with anticonvulsant medication, there are some
patients with seizures that are difficult to control.
Seizures related to acute intraparenchymal cysticercosis are usually associated with other
neurological signs and tend to disappear when edema and acute inflammation subside. In this situation,
seizures can be considered as acute symptomatic and not necessarily fulfil the criteria for diagnosis
of epilepsy.
Chronic intraparenchymatous lesions of neurocysticercosis consists of viable cysts or, more
frequently, the cicatricial form of small nodular calcifications. The epilepsies associated with
calcifications of neurocysticercosis are in general easy to control and many patients present with
remission of seizures after a few years. However, due to the high incidence of neurocysticercosis in
underdeveloped countries, it is common the finding of microcalcifications in computerized
tomography (CT) of asymptomatic individuals and in patients with other forms of epilepsies, such
as temporal lobe epilepsy associated with mesial temporal sclerosis or primary generalized epilepsies.
In these situations, the role of calcifications of neurocysticercosis in epileptogenesis is still unclear.
On the other hand, patients with chronic viable cystic lesions of neurocysticercosis, often present
with partial seizures, and there are some indications that these are related to the location of the cysts.
It is impossible to predict how long these cysts can stay “viable” in the cerebral parenchyma, but
some suggest that they should not be treated 1-3.
The purpose of this study was to evaluate the clinical features of one particular form of
neurocysticercosis related seizures, the chronic viable cortical cysts, as well as the effect of cysticidal
therapy on cystic regression and seizure control.
METHOD
Criteria for selection -  We included 18 patients followed at the epilepsy clinic at the Hospital das Clínicas,
UNICAMP, with the diagnose of epilepsy and intraparenchymatous cysts of cysticercosis. Although all patients
were on antiepileptic medication, they were not seizure free (a minimum of 3 seizures / year). All patients
underwent at least 2 head CT previous to cysticidal therapy, and follow up imaging after treatment with CT or
magnetic resonance imaging (MRI).
Exclusion criteria were - Patients with less than 3 seizures per year; and those who did not complete the
cysticidal therapy; or underwent only one CT during follow up period.
Seizure classification followed the criteria of the International League Against Epilepsy (ILAE) 12.
Cerebrospinal fluid  (CSF) analysis - All the patients underwent cytology, biochemistry analysis and
immunological test for cysticercosis (indirect immunofluorescence in 3 and ELISA in 15).
Electroencephalogram  (EEG) - An interictal EEG was performed on all patients using equipment with
16 channels and the 10-20 electrode system for electrodes placement.
All patients had at least 2 CTs with and without contrast at different times during follow up. Nine patients
had also MRI with gadolinium. Images were obtained using T1 and T2 weighted sequences in axial, sagittal and
coronal planes.
Cysticidal therapy - 16 patients were given a dose of 15-20 mg/kg of albendazol for 7 to 30 days (median
=21 days; mean = 18 days) and 2 patients were treated with 50 mg/kg of praziquantel for 15 days. Five days
before the cysticidal treatment began they received 1 mg/kg of prednisone. Predinisone was maintained during
the cysticidal treatment and tapered down afterwards. Follow up after the treatment varied from 5 months to 12
years (mean = 33 months).
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Table 1. Classification of seizures - 18 patients*.
Seizure semiology Nº of Patients %
SPS somatosensory 6 33,4
SPS special sensory 5 27,8
SPS autonomic 1 5,5
SPS psychic 2 11,1
SPS versive 1 5,5
CPS 3 16,7
Total 18 100
SPS, simple partial seizures: CPS, complex partial seizures. *All patients had
presented secondary generalized tonic-clonic seizures
Fig 1. Persistence of frontal cysts in CT series taken over a period of 77 months and cyst resolution
after cysticidal therapy: 1A: CT of the cranium performed in June, 1992, showed frontal cystic
lesions and multiple calcifications. 1B: CT performed in August , 1993, showed a right frontal
cyst (a left frontal cyst was observed in a section above). 1C: CT performed in November, 1998,
showed that the left frontal cyst persisted (the right frontal cyst was observed in a section below).
1D: Cysticidal therapy terminated in February, 1999. The MRI done in March, 1999, showed
that the cysts had disappeared.
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Fig 2. Cyst resolution in a patient who was immediately put on cysticidal therapy: 2A: MRI performed in
April, 1998, showed a cystic lesion in the left frontal region, the patient was immediately put on cysticidal
therapy. 2B: MRI from May, 1998, - 3 weeks after terminating the cysticidal therapy the left frontal cyst had
decreased in size. 2C: MRI from December, 1998, - 8 months after terminating the cysticidal treatment the
cyst had disappeared completely.
RESULTS
Clinical features - The follow-up period varied from 3 months to 12 years. The patients’ ages
ranged from 19 to 70 years (mean = 36.4 years). Seizure onset varied from 2 years to 62 years (mean
= 21 years). The duration of epilepsy varied from 3 months to 36 years (mean = 16 years). Fifteen
patients (83%) had simple partial seizures (SPS); 11 (61%) had somatosensory and special sensory
manifestations; 3 (17%) had complex partial seizures (CPS). All 18 patients had secondary
generalizations (Table 1).
Six (33%) patients had pleocytosis on the CSF exam; 5 (28%) had elevated protein levels and
only 4 (22%) had positive immunology for cysticercosis.
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EEG showed focal epileptiform abnormality in 5 patients (28%); focal slow wave abnormalities
in 5 (28%); generalized slow wave abnormalities in one (5%), and it was normal in 7 patients (39%).
A relationship between focal changes and cyst location was observed in only 5 patients (28%).
CT or MRI or both showed a single cystic lesion in 2 patients (11%) and multiple cysts in 16
patients (89%). Additional micro-calcifications were present in 14 patients (78%).
In 11 patients we were able to document with repeated CTs the persistence of cystic lesions
for an average of 4.2 years (ranging from 8 to 86 months) prior to the cysticidal treatment. Cyst
persistence with contrast uptake was observed in 50% of the cases for an average period of 36.4
months (Fig 1). It was not possible to estimate for how long the cysts were present in 8 patients
because they opted for immediate treatment (Fig 2).
After treatment, the cysts disappeared in 13 patients (72%), and reduced significantly in size
or number in the remaining 5 patients (28%).
There was a relationship between the location cysts and seizure semiology in all patients who
had somatosensory and special sensory seizures.
Seizure control after cysticidal treatment - Total seizure control was obtained in 5 patients
(28%), a partial control (at least 50% reduction in the number of seizures) in 10 patients (55%), and
in the remaining 3 patients (17%) seizure frequency remained unchanged. During follow up, the
same antiepileptic medication was maintained in 13 patients (72%).
DISCUSSIONI I
Although the methodology used in studies that evaluate efficacy praziquantel and albendanzol
for treatment of cysticercosis has received criticisms 1, 2, 14-16, their use in the cysticidal treatment of
neurocysticercosis has proved efficacious 10,13. Although neurocysticercosis is widespread in
underdeveloped countries with an important socioeconomical impact, there is a lack of information
about its natural history, treatment and prognosis 1,17.
The controversies concerning epilepsy related to neurocysticercosis are even greater, partly
because of different forms of pathological manifestations of the infection (parenchymal and
extraparenchymal; active and inactive; meningeal and intraventricular). The coexistence of other
pathologies creates methodological difficulties in studying these patients 1,18.
This study did not aim to clarify the controversies about epilepsy related to neurocysticercosis
but to report the seizure outcome after cysticidal therapy in a group of these patients. There are
obvious constrains that prevent a sizeable prospective placebo controlled study to investigate the
real efficacy of albendazol or praziquantel for treating patients with active neurocysticercosis. First,
given the complex variability of the individual immunologic response to the parasite, and sites of
infection (parenchyma, ventricles, subarachnoid space), it would be necessary a quite large number
of patients for a valid conclusion. In addition, it would be necessary follow-up of imaging and CSF
evaluation to prove the efficacy of treatment. Such a study would be prohibitively expensive.
Furthermore, common sense indicates that investing in education and improvement of sanitary
conditions in order to prevent or even eradicate this disease would be more productive. Given the
difficulties mentioned above, we believe that there could not be a more appropriate control group
than the study group itself, despite of all the methodological limitations.
It has been observed that epilepsy related to neurocysticercosis usually occurs in young
economically active individuals 7,10 and therefore, causes a tremendous social impact in developing
countries. Conventional antiepileptic drugs besides being expensive do not always satisfactorily
control their seizures. Various factors that have been present prior to treatment like multiple cysts,
calcification and recurring seizures seem to have a negative influence on seizure control 6.
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We evaluated the average duration of epilepsy, type and frequency of seizures, and how long
the active cysts were present before treatment. In this study we observed that seizure control improved
significantly in 83% of the patients after cysticidal treatment, even though they had a longstanding
seizure disorder (mean duration of epilepsy of 16.2 years). Despite the small number of patients,
these results support the indication for cysticidal treatment for patients with cortical active cysts,
even in those with a long history of epilepsy.
In this study partial seizures were predominant, especially simple somatosensory and special
sensory seizures, in agreement with previous studies 10,20-22. We also observed a direct relationship
between seizure symptoms and the location of cysts, which strengthens the cause–effect relationship
between cysts and epilepsy in these patients.
The most sensitive diagnostic methods are the CT and MR - MR being superior to the CT
except in detecting associated multiple punctiform calcifications1,18,22-26 . In most of these patients
with parenchymatous cysticercosis, the CSF was normal 27. The EEG did not show specific
abnormalities and in some of the patients the results were normal 2,6,18.
In those patients with repeated CTs, the average period of persistence of parenchymal cysts
was 50.6 months. This demonstrates the difficulty in defining how long would be necessary for the
spontaneous resolution of cysts on an individual basis, even when there is contrast enhancement.
This can take weeks or years1, 5,20,28-30 but can be shortened by a few days or weeks with cysticidal
therapy 20,31,32, with the additional improvement of seizure control in many of these patients as
demonstrated here.
Conclusion
Cysticidal treatment can help in controlling seizures in partial epilepsies related to the presence
of active neurocysticercosis in the cerebral cortex, independent of the results of CSF exam and the
pattern of contrast uptake on CT or MRI. Treatment with albendazol, and alternatively praziquantel,
should be considered in patients with epilepsy related to active cerebral cysticercosis, particularly
when the site of seizure onset coincides with the location of the cysts.
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